MedPath

Lamotrigine

Generic Name
Lamotrigine
Brand Names
Lamictal
Drug Type
Small Molecule
Chemical Formula
C9H7Cl2N5
CAS Number
84057-84-1
Unique Ingredient Identifier
U3H27498KS

Overview

Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.

Background

Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.

Indication

Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome. It is also indicated for the process of conversion to drug monotherapy for those at least 16 years of age or older with partial seizures and currently are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). In addition to the above, lamotrigine is also indicated for the maintenance treatment of bipolar I disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes) in adults at least 18 years or older, who have been treated for acute mood symptoms with standard therapy. Limitations of use It is important to note that lamotirigine should not be used in the treatment of acute mood episodes, as efficacy has not been established in this context.

Associated Conditions

  • Bipolar 1 Disorder
  • Generalized Tonic-Clonic Seizures
  • Partial-Onset Seizures
  • Seizures, Generalized

FDA Approved Products

Lamotrigine
Manufacturer:Northstar Rx LLC.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/04/05
NDC:16714-195
Lamotrigine
Manufacturer:Northstar Rx LLC.
Route:ORAL
Strength:150 mg in 1 1
Approved: 2023/04/05
NDC:16714-196
Lamotrigine
Manufacturer:Northstar Rx LLC.
Route:ORAL
Strength:25 mg in 1 1
Approved: 2023/04/05
NDC:16714-194
Lamotrigine
Manufacturer:Alembic Pharmaceuticals Inc.
Route:ORAL
Strength:150 mg in 1 1
Approved: 2022/08/04
NDC:62332-039
Lamotrigine
Manufacturer:Alembic Pharmaceuticals Inc.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2022/08/04
NDC:62332-038

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath